OncoSec Medical Inc. (OTCBB: ONCS) rated to Buy with price target $3 by Maxim Group
Maxim Group rated OncoSec
Medical Inc. (OTCBB: ONCS) to Buy with price target $3.
OncoSec Medical Inc. innovative ElectoOncology tumor therapies are designed to improve patient treatment outcomes and quality of life, compared to conventional therapy options, such as surgery, radiation, and chemotherapy. Utilizing the Company's propietary electroporation delivery system, uptake of the Company's chmeotherapeutic and DNA immunotherapieutc anti-cancer agents into cancerous cells is dramtically ehhanced. Clinical experience in early and late stage trials with over 400 patients have demonstrated selective destruction of cancerous cells, while sparing healthy normal tissues, and minimizing adverse effects experienced through convential modes of therapy. The Company is planning advanced stage clinical studies of its potentially life -altering ant-cancer therapies to begin by the end of 2011.
At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.